Beta Drugs (NSE:BETA) ROCE %: 16.28% (As of Mar. 2026)


NSE:BETA Beta Drugs Ltd NSE:BETA
82 GF Score
Price ₹2,096.60
GF Value ₹1,960.95
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs ROCE %?

Beta Drugs NSE:BETA -3.13% 82 ROCE % is 16.28% as of Mar. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 82/100 and a GF Value™ of ₹1,960.95 (Fairly Valued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Beta Drugs's annualized ROCE % for the quarter that ended in Mar. 2026 was 16.28%.

Beta Drugs  (NSE:BETA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Beta Drugs ROCE % Related Terms

Beta Drugs ROCE % Historical Data

* Premium members only.

The historical data trend for Beta Drugs's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs ROCE % Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 37.38 35.48 33.74 25.43 19.33

Beta Drugs Quarterly Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28.06 18.61 0.00 15.97 16.28
NSE:BETA
82GF Score
Beta Drugs Ltd NSE:BETA
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs ROCE % Calculation

Beta Drugs's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=697.048/( ( (4362.347 - 1027.296) + (4957.996 - 1081.404) )/ 2 )
=697.048/( (3335.051+3876.592)/ 2 )
=697.048/3605.8215
=19.33 %

Beta Drugs's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=631.024/( ( (0 - 0) + (4957.996 - 1081.404) )/ 1 )
=631.024/( ( 0 + 3876.592 )/ 1 )
=631.024/3876.592
=16.28 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.28% mean?
Beta Drugs (NSE:BETA) has a ROCE % of 16.28% as of Mar. 2026.
Is Beta Drugs' ROCE % too high?
Beta Drugs' current ROCE % is 16.28%. The Drug Manufacturers industry median ROCE % is 7.00. Beta Drugs' value of 16.28% is 132.7% above this industry median. Overall, Beta Drugs has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' ROCE % compare to ZTS?
Beta Drugs' ROCE % of 16.28% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Beta Drugs' value of 16.28% is 132.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Drug Manufacturers company?
The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current ROCE % of 16.28% is 132.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current ROCE % is 16.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,960.95, compared to a current price of ₹2,096.60 — trading 6.9% above its estimated fair value. The current ROCE % is 16.28% and 132.7% above the Drug Manufacturers industry median of 7.00. Beta Drugs' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current ROCE % is 16.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,096.60 is trading 6.9% above its estimated GF Value™ of ₹1,960.95. GuruFocus considers Beta Drugs to be Fairly Valued.

Key valuation signals for NSE:BETA:

  • ROCE %: 16.28%
  • GF Value™: ₹1,960.95 vs. price of ₹2,096.60 (6.9% above fair value)
  • GF Score™: 82/100 with 6 warning signs
  • Industry Position: 132.7% above the Drug Manufacturers median

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
82GF Score

Get the complete analysis for NSE:BETA

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,096.60
Price
₹1,960.95
GF Value